SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-103813
Filing Date
2024-09-30
Accepted
2024-09-27 19:56:21
Documents
18
Period of Report
2024-09-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2425109d1_8k.htm   iXBRL 8-K 41299
2 EXHIBIT 1.1 tm2425109d1_ex1-1.htm EX-1.1 45842
3 EXHIBIT 4.1 tm2425109d1_ex4-1.htm EX-4.1 90051
4 EXHIBIT 4.2 tm2425109d1_ex4-2.htm EX-4.2 87058
5 EXHIBIT 10.1 tm2425109d1_ex10-1.htm EX-10.1 207228
6 EXHIBIT 99.1 tm2425109d1_ex99-1.htm EX-99.1 10615
  Complete submission text file 0001104659-24-103813.txt   777654

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA syn-20240926.xsd EX-101.SCH 3042
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20240926_lab.xml EX-101.LAB 34240
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20240926_pre.xml EX-101.PRE 22378
20 EXTRACTED XBRL INSTANCE DOCUMENT tm2425109d1_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 241336298
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)